Multicomponent IOL provides excellent vision

Article

Multicomponent IOL implantation is safe, easy and provides excellent vision, according to a recent case series.

Multicomponent IOL implantation is safe, easy and provides excellent vision, according to a recent case series.

Dr Portaliou et al., Institute of Vision and Optics, University of Crete School of Medicine, Heraklion, Crete, Greece, conducted an initial evaluation of six patients who underwent routine cataract surgery and multicomponent IOL implantation. Surgical implantation technique, the manufacturing feasibility of the IOL and the incidence of interlenticular fibrosis were all evaluated.

There were no intraoperative or postoperative complications and no cases of interlenticular fibrosis. The outcomes produced no statistically significant differences in endothelial cell density, anterior chamber depth or pachymetry readings throughout the two-year study.

Multicomponent IOL implantation is an efficient, successful and safe procedure for patients undergoing routine cataract surgery.

To find out more please visit the Journal of Cataract and Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.